- Business
- Zhejiang Huahai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), pharmaceutical preparations, intermediates, packaging components, and related services; Zhejiang Huahai Pharmaceutical Co., Ltd. operates globally from its headquarters in Linhai, Zhejiang Province, China, where it was founded in 1989, with over 40 subsidiaries and branches in countries including the United States, Japan, Germany, Russia, Spain, and India. The company's core products encompass APIs and preparations focused on cardiovascular therapies such as irbesartan, losartan potassium, olmesartan medoxomil, valsartan, telmisartan, and amlodipine; central nervous system drugs including paroxetine hydrochloride, olanzapine, duloxetine hydrochloride, bupropion hydrochloride, and levetiracetam; anti-viral and anti-infective agents like oseltamivir phosphate, efavirenz, voriconazole, and doxycycline hydrochloride; as well as oncology products such as epirubicin hydrochloride injection, alongside biopharmaceuticals in autoimmunity and oncology fields, generic drugs across digestive, respiratory, endocrine, and anti-cancer categories, and contract manufacturing organization (CMO) services. Zhejiang Huahai Pharmaceutical Co., Ltd. serves over 500 pharmaceutical partners worldwide, supplying products to approximately 200 countries and regions, with significant export markets in North America, Europe, and Asia representing over 50% of sales. In recent developments, a subsidiary received US FDA good manufacturing practice pre-approval inspection in September 2025; the company reported nine-month sales of CNY 6.41 billion as of September 30, 2025; Zhejiang Huahai Pharmaceutical Technology Co., Ltd. announced a CNY 200 million funding round in March 2025 with participation from the parent company; and ongoing investments include R&D expansions and international production capacity, such as a 7 billion tablets facility in Charlotte, US.